Patents Examined by Julie Ha
-
Patent number: 11993640Abstract: Described herein are compositions and methods for treating pulmonary fibrosis and cancer. The compositions include growth hormone releasing hormone peptides. The methods include reducing lung inflammation, lung scarring, reducing expression of T cell receptor complex genes as well as inhibiting tumor growth.Type: GrantFiled: August 6, 2021Date of Patent: May 28, 2024Assignee: The United States Government as Represented by the Department of Veterans AffairsInventors: Robert M. Jackson, Andrew V. Schally, Renzhi Cai
-
Patent number: 11986514Abstract: This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema.Type: GrantFiled: August 31, 2018Date of Patent: May 21, 2024Assignees: INSERM (INSTITUT NATIONAL DE LASANTE ET DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITE, UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: Francine Behar-Cohen, Raphael Cohen, Rinath Levy-Boukris, Min Zhao
-
Patent number: 11987608Abstract: Provided is a composition for accelerating cell proliferation, including an erythropoietin-derived peptide as an active ingredient. Due to having a simpler structure than that of the existing natural human erythropoietin, the composition easily passes through the tissue-blood barrier, exhibits excellent cell protective activity, does not cause side effects of cell proliferation, and improves a hematopoietic function. Accordingly, the composition is used in the treatment or prevention of an anemic disorder.Type: GrantFiled: August 21, 2019Date of Patent: May 21, 2024Assignee: SYLUS CO., LTD.Inventors: Che Il Moon, So Yeon Kim, Seung Jun Yoo, Bong Ki Cho
-
Patent number: 11986513Abstract: GAL(1-15) and analogues thereof for use in the prevention and/or treatment of alcohol-related effects and disorders. The present invention relates to the use of galanin(1-15), which has the general formula Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala (GWTLNSAGYLLGPHA)(SEQ ID NO: 1), or an analogue thereof, or pharmaceutically acceptable salt, ester, tautomer, solvate, or hydrate thereof, or a pharmaceutical composition or kit comprising any of same, for use in the prevention and/or treatment of alcohol-related effects and disorders, especially the use thereof to reduce alcohol consumption.Type: GrantFiled: October 2, 2018Date of Patent: May 21, 2024Assignee: UNIVERSIDAD DE MÁLAGAInventors: Carmelo Millón Peñuela, Antonio Flores Burgess, Belén Gago Calderón, María Inmaculada García Fernandez, José Ángel Narváez Bueno, Luis Javier Santín Núñez, Mª Zaida Díaz Cabiale
-
Patent number: 11981723Abstract: A method of targeting extracellular vesicles employing a molecule comprising a GLA domain and extracellular vesicles obtained or obtainable from a method are described herein.Type: GrantFiled: September 5, 2018Date of Patent: May 14, 2024Assignee: GLADIATOR BIOSCIENCES, INC.Inventors: Terry Hermiston, Maxine Bauzon, Christopher H. Contag, Jonathan Hardy, Masamitsu Kanada
-
Patent number: 11981752Abstract: Disclosed are compositions and methods useful for targeting molecules to activated macrophages, such as tumor associated macrophages. The compositions and methods are based on peptide sequences, such as AMT peptides, that home to activated macrophages. The disclosed homing to activated macrophages is useful for delivering therapeutic and detectable agents to cells and tissues where immune system effects or inflammation are occurring.Type: GrantFiled: May 1, 2018Date of Patent: May 14, 2024Assignee: Sanford Burnham Prebys Medical Discovery InstituteInventors: Hongbo Pang, Erkki Ruoslahti
-
Patent number: 11975040Abstract: The present invention provides a Plexin-binding regulating agent containing a cyclic peptide having an Arg-Trp-Thr structure or a Leu-Ser-Trp structure or a pharmaceutically acceptable salt of the cyclic peptide.Type: GrantFiled: June 16, 2017Date of Patent: May 7, 2024Assignees: The University of Tokyo, Osaka UniversityInventors: Hiroaki Suga, Nasir Kato Bashiruddin, Junichi Takagi, Yukiko Matsunaga
-
Patent number: 11965011Abstract: An antitumor peptide provided according to the present invention includes (1) an S1PR-TM related sequence; and (2) an amino acid sequence functioning as a cell penetrating peptide; wherein the total number of amino acid residues is 100 or less.Type: GrantFiled: June 28, 2022Date of Patent: April 23, 2024Assignees: Toagosei Co., LTD, National University Corporation Nagoya UniversityInventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Makoto Sawada
-
Patent number: 11964000Abstract: Provided herein are compositions comprising peptide amphiphiles, glycosylated peptide amphiphiles (GPAs), supramolecular nanostructures assembled therefrom, and methods of use thereof. The peptide amphiphiles described herein may extend the half-life of bone morphogenic proteins, promote cell differentiation, suppress proliferation, and increase chemosensitivity of cells. Accordingly, the compositions described herein may be used for cancer treatment methods. In particular, provided herein are bone morphogenic proteins bound to peptide amphiphiles and glycosylated peptide amphiphiles or composites thereof, and methods of use of the same for the treatment of cancer. Also, provided herein are bone morphogenic proteins bound to peptide amphiphiles and glycosylated peptide amphiphiles or composites thereof, and methods of use of the same in a combinatorial approach together with chemotherapeutic medications for the treatment of cancer.Type: GrantFiled: April 12, 2021Date of Patent: April 23, 2024Assignee: Northwestern UniversityInventors: Samuel I. Stupp, Mark Trosper McClendon, Guifa Xi, Bo Timmy Bjoern Fyrner, Cara S. Smith, Nicholas A. Sather
-
Patent number: 11965041Abstract: The present invention provides N-methylated cyclic hexapeptides comprising RGD and at least one alanine residue. The present invention further provides prodrugs comprising the cyclic hexapeptides. Pharmaceutical compositions comprising said cyclic hexapeptides are also disclosed as well as methods of their production and use in treating integrin related conditions and diseases.Type: GrantFiled: September 17, 2018Date of Patent: April 23, 2024Assignee: TECHNISCHE UNIVERSITAET MUENCHENInventors: Horst Otto Kessler, Chaim Gilon, Amnon Hoffman, Michael Weinmuller, Florian Rechenmacher, Joseph Fanous, Adi Klinger
-
Patent number: 11957737Abstract: Methods of treating or preventing microbial infection in a subject in need of treatment by administering a therapeutically effective amount of ergothioneine, or functional analog, or prodrug, or salt thereof. Ergothioneine may be advantageously administered in conjunction with lactoferrin.Type: GrantFiled: June 30, 2022Date of Patent: April 16, 2024Assignees: COLORADO SEMINARY, OWNER AND OPERATOR OF UNIVERSITY OF DENVER, THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: John Repine, Amani Alhalwani
-
Patent number: 11959486Abstract: A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.Type: GrantFiled: August 11, 2021Date of Patent: April 16, 2024Assignee: Amgen Inc.Inventors: Derek Maclean, Qun Yin
-
Patent number: 11951150Abstract: The present invention relates to compositions and methods for preventing and reducing inflammation and preventing and treating diseases and disorders associated with inflammation. It has been shown that CRADD plays a pivotal role in maintaining the integrity of endothelial monolayers. The recombinant cell-penetrating CRADD protein (CP-CRADD)-based compositions and methods described herein provide for the development of a novel treatment for inflammatory vascular disorders including cardiovascular, cerebrovascular, respiratory, gastrointestinal, and renal systems.Type: GrantFiled: June 7, 2021Date of Patent: April 9, 2024Assignee: Vanderbilt UniversityInventors: Jack J. Hawiger, Ruth Ann Veach, Yan Liu, Huan Qiao, Lukasz S. Wylezinski
-
Patent number: 11951155Abstract: A pea-derived peptide with a muscle-building effect and a preparation method thereof, and a drug and use, are disclosed. A pea protein is subjected to enzymatic hydrolysis, and five polypeptides with muscle-building effect are obtained by separation as separate peptide fragments. In an in vitro aging skeletal muscle cell assay, changes are analyzed in a gene expression level of regulatory pathways related to skeletal muscle cell proliferation and differentiation, apoptosis and autophagy, and protein synthesis and degradation. In addition, animal experiments are conducted to study the muscle-building effect and a corresponding mechanism of the pea-derived peptide. This shows that the five polypeptide sequences have a significant muscle-building effect, usable as a polypeptide drug for the treatment of sarcopenia.Type: GrantFiled: August 22, 2022Date of Patent: April 9, 2024Assignee: Zhongshi Duqing(Shandong) Biotech Co., LtdInventors: Zhao Zhang, Jiuxun Zhang, Zheng Zhang, Jie Li, Wei Wei, Xiping Zhang, Zhongli Pei, Shuai Gu, Lizhu Niu
-
Patent number: 11952407Abstract: Preparations including recombinant FSH (rFSH).Type: GrantFiled: April 30, 2021Date of Patent: April 9, 2024Assignee: FERRING INTERNATIONAL CENTER S.A.Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
-
Patent number: 11951149Abstract: Provided herein are methods for treating, reducing and/or ameliorating symptoms of autism spectrum disorder (ASD) in a subject, where at least one measure of social impairment, anxiety, or repetitive behaviors is treated and/or ameliorated. Aspects include intranasally administering arginine vasopressin (AVP), or an analog of vasopressin, to a subject (e.g., a child between 6 and 12 years of age and having endogenous pre-treatment levels between about 0.045 and about 4.028 pg/mL, where the mean was 1.324 pg/mL). In children having high pre-treatment blood levels of AVP (e.g., about 25% or more above the mean pre-treatment AVP blood levels of the treatment group; or having pre-treatment blood vasopressin levels greater than 1.324 pg/mL), the treatment was enhanced. Because no difference in pre-treatment blood AVP levels was observed between control and ASD subjects, it was surprising that AVP treatment was more effective in subjects having high pre-treatment AVP levels.Type: GrantFiled: July 10, 2019Date of Patent: April 9, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Karen J. Parker, Dean S. Carson, Antonio Y. Hardan
-
Patent number: 11952415Abstract: The invention relates to a polypeptide, such as an Affimer polypeptide, comprising an amino acid sequence having at least 80% identity to amino acid residues 1 to 11, 13 to 15, 17 to 19, 21 to 25, 27 to 28, 35 to 37, 39, 41, 43 to 44, 46 to 47, 49 to 50, 52 to 53, 55 to 58, 63 to 64, 66, 68 to 82, 84 to 85, and 87 to 98 of SEQ ID NO: 1; characterised in that said polypeptide comprises one or more mutations relative to SEQ ID NO: 1 selected from the group consisting of: T51L, T51V, M65V, N32G, A59I, L38A, V20I, A40I, L38V, A12I, A12V, I16L, V20L, Q26E, E29M, T31K, N32D, N32H, T34V, T34R, T34D, T34P, A40V, Q42D, T45I, T45V, V48E, V48G, V48A, T51F, T51A, A59L, L67I, (V20I, L38A), (V20L, L38A), (V20I, L38V), (V20L, L38V), (E29K, K30E, E33K), (Y54D, T83D, Q86E), (A59L, G60N, D61G, N62K), (A59V, D61N, N62K), (G60N, D61G, N62K), (G60N, ?D61, N62G), ?D61, (A59L, G60N, ?D61, N62G), (A59V, G60N, D61G, N62K), (A59I, G60N, D61G, N62K), (A59I, G60N, ?D61, N62G), (A59V, G60N, ?D61, N62G), (A59V, ?D61), (G60P, ?D61, N62P),Type: GrantFiled: July 2, 2018Date of Patent: April 9, 2024Assignee: Avacta Life Sciences LimitedInventors: Geoffrey William Platt, Graham Robert Pye-Smith Spence
-
Patent number: 11944688Abstract: The invention relates to improvements in drug delivery and more particularly to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to form Stapled CPP's (StaP's) or ii) stitching three or more amino acids to form stitched CPP's (StiP's). These stabilized CPP's are conjugated to a drug or Biologically Active Compound (BAC) directly or via a Bi-Functional Linker (BFL) so that the BAC can be carried though a cell membrane by the CPP. The resulting molecules are referred to as Drug Carrying Cell Penetrating Molecules (DCCPM's). The preferred BAC is an electrically low charge carrying oligonucleotide such as a phosphorodiamidate morpholino oligonucleotide (PMO).Type: GrantFiled: December 27, 2022Date of Patent: April 2, 2024Assignee: SUTURA THERAPEUTICS LTDInventors: Keith Foster, Wouter Eilers, Adam James Reginald Gadd
-
Patent number: 11938198Abstract: The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAP?. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAP? to which PP2A binds.Type: GrantFiled: March 13, 2020Date of Patent: March 26, 2024Assignees: University of Miami, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Michael S. Kapiloff, Jinliang Li
-
Patent number: 11939403Abstract: Molecular scaffolds, including cyclic peptides, that have high (large) cell permeability.Type: GrantFiled: July 2, 2021Date of Patent: March 26, 2024Assignee: The Regents of the University of CaliforniaInventors: R. Lokey, Akihiro Furukawa